Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Calcitonin gene-related peptide and pituitary adenylate cyclase-activating polypeptide in migraine treatment

Research output: Contribution to journalReviewResearchpeer-review

  1. Long-acting amylin analogues for the management of obesity

    Research output: Contribution to journalReviewResearchpeer-review

  2. Hashimoto's thyroiditis as a risk factor for thyroid cancer

    Research output: Contribution to journalReviewResearchpeer-review

  3. Gut hormones in the treatment of short-bowel syndrome and intestinal failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Updates in weight loss surgery and gastrointestinal peptides

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Involvement of adenosine signaling pathway in migraine pathophysiology: A systematic review of clinical studies

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. PACAP38- and VIP-induced cluster headache attacks are not associated with changes of plasma CGRP or markers of mast cell activation

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Imaging the inflammatory phenotype in migraine

    Research output: Contribution to journalReviewResearchpeer-review

  4. Is calcitonin gene-related peptide a reliable biochemical marker of migraine?

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

PURPOSE OF REVIEW: To review the latest advances in migraine management with a focus on medications specifically developed for the treatment of migraine.

RECENT FINDINGS: Randomized clinical trials demonstrated the efficacy of calcitonin gene-related peptide (CGRP) mAbs for the preventive treatment of migraine and the small molecule CGRP receptor antagonist gepants for acute abortion and prevention of migraine attacks. Pituitary adenylate cyclase-activating polypeptide (PACAP) is another signaling molecule of interest and represents a potential new drug class of mechanism-based migraine medications. Drugs targeting PACAP are currently undergoing clinical trials, and the coming years will reveal whether this class of drugs will expand our therapeutic armamentarium.

SUMMARY: Here, we summarize the role of CGRP and PACAP in migraine pathophysiology and discuss novel therapies targeting the CGRP and PACAP signaling pathways.

Original languageEnglish
JournalCurrent Opinion in Endocrinology, Diabetes and Obesity
Volume29
Issue number2
Pages (from-to)225-231
Number of pages7
ISSN1752-296X
DOIs
Publication statusPublished - 1 Apr 2022

Bibliographical note

Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

ID: 73907615